MarketCap
Facebook
X
TelegramAuris Medical Holding Ltd. Operating Expenses 2011-2026 | EARS
Annual Operating Expenses Auris Medical Holding Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | 7.26 M | 11 M | 24.4 M | 30.2 M | 30.9 M | 21.4 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.9 M | 7.26 M | 20.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.61 | -0.35 % | $ 85.1 M |  USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.73 | 1.78 % | $ 8.97 B |  Australia |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 98.83 | 2.2 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.68 | 4.34 % | $ 760 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.25 | 1.41 % | $ 327 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.47 | 0.51 % | $ 1 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.53 | 3.74 % | $ 393 M | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.83 | 0.91 % | $ 27.9 M |  Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
|
Forte Biosciences
FBRX
|
70.7 M | $ 32.98 | 7.76 % | $ 427 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.05 | 4.45 % | $ 5.02 M | Israel |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.13 | -1.43 % | $ 442 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 25.25 | 4.68 % | $ 3.21 B | USA |
 |
Chimerix
CMRX
|
93.4 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
110 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 33.25 | 2.03 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.49 | 1.02 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
Galectin Therapeutics
GALT
|
20.1 M | $ 2.45 | 4.26 % | $ 157 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.51 | - | $ 1.11 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |